Clinical Trials Using Vemurafenib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Vemurafenib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-13 of 13
  • Vemurafenib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

    This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body (advanced) and have come back (recurrent) or do not respond to treatment (refractory). Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 113 locations

  • Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma

    This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 91 locations

  • TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). ********************************************************************************************* ********************************************************************************* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org / news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. ********************************************************************************************* *********************************************************************************
    Location: 10 locations

  • Vemurafenib and Obinutuzumab in Treating Patients with Previously Untreated Classical Hairy Cell Leukemia

    This phase II trial studies how well vemurafenib and obinutuzumab work in treating patients with previously untreated classical hairy cell leukemia. Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Obinutuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread Giving vemurafenib and obinutuzumab may work better in treating patients with previously untreated hairy cell leukemia.
    Location: 9 locations

  • Vemurafenib plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

    This purpose of this phase Ib trial is to develop a new drug treatment to reverse resistance to radioiodine therapy in treating patients with BRAF gene mutated thyroid cancer that does not respond to radioiodine therapy alone (radioiodine-refractory), so that radioiodine can be given to shrink these tumors. BRAF gene mutation in thyroid cancer makes it unlikely to respond to radioiodine therapy. This trial investigates the highest doses of copanlisib and vemurafenib that, when given in combination, do not cause serious side effects, and whether the study treatment will make radioiodine therapy work better in patients with BRAF-mutant thyroid cancers. Iodine-124 (I-124) is used only to detect thyroid cancers on imaging studies called positron emission tomography / computed tomography (PET / CT) scans. Iodine-131 (I-131) is used to detect thyroid cancers on scans and to shrink thyroid tumors. Some tumors do not absorb enough (I-131) to cause them to shrink. In some tumors, mutation of the BRAF gene is the primary reason I-131 cannot be absorbed and why it does not shrink those tumors. Vemurafenib inhibits BRAF, and in some patients this drug can increase the amount of radioiodine taken up by tumors with BRAF mutations. Copanlisib blocks PI3K, which is a protein that causes radioiodine resistance by forcing thyroid cancer cells to eliminate radioiodine before it can deliver radiation to kill the tumor. Giving copanlisib and vemurafenib may cause radioiodine to be better absorbed and held longer in thyroid cancer cells, making radioiodine treatment more effective in treating patients with BRAF-mutant thyroid cancers.
    Location: 7 locations

  • A Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Participants With Stages I-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, or BRAF v600E Molecular Alterations

    This trial will evaluate the efficacy and safety of targeted therapies in participants with resectable Stage IA2, IB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors with selected molecular alterations.
    Location: 8 locations

  • A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

    This is a phase 2 / 3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.
    Location: 5 locations

  • Vemurafenib, Cobimetinib, and Atezolizumab in Treating Patients with High-Risk Stage III Melanoma

    This early phase I pilot trial studies how well vemurafenib, cobimetinib, and atezolizumab work in treating patients with high-risk stage III melanoma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vemurafenib, cobimetinib, and atezolizumab may work better in treating high-risk stage III melanoma.
    Location: 3 locations

  • Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

    This phase Ib trial determines if samples from a patient’s cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Vemurafenib and Cobimetinib in Treating Participants with BRAF Mutant Stage IIIC-IV Melanoma

    This pilot early phase I trial studies how well vemurafenib and cobimetinib work in treating participants with BRAF mutant stage IIIC-IV melanoma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Atezolizumab with Chemotherapy in Treating Patients with Anaplastic or Poorly Differentiated Thyroid Cancer

    This phase II trial studies how well atezolizumab in combination with chemotherapy works in treating patients with anaplastic or poorly differentiated thyroid cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vemurafenib and cobimetinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of cancer cells to grow and spread. Drugs such as nab-paclitaxel and paclitaxel work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to see if atezolizumab in combination with chemotherapy works better in treating patients with anaplastic or poorly differentiated thyroid cancer compared to standard treatments.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

    - An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered with an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients with Advanced or Inoperable Malignant Melanoma with BRAF Mutation - The primary objective is to determine the safety, maximum tolerated dose (MTD), and dose limiting toxicity (DLT) of the co-administration of P1446A-05 with vemurafenib, in melanoma patients with BRAF mutation
    Location: See Clinical Trials.gov

  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

    This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and / or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
    Location: 161 locations